Literature DB >> 25810300

Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis.

Weihua Guan1, Jing Cao1, Brian T Steffen1, Wendy S Post1, James H Stein1, Mathew C Tattersall1, Joel D Kaufman1, Joseph P McConnell1, Daniel M Hoefner1, Russell Warnick1, Michael Y Tsai2.   

Abstract

OBJECTIVE: We aimed to examine associations of lipoprotein(a) (Lp(a)) concentrations with coronary heart disease (CHD) and determine whether current Lp(a) clinical laboratory cut points identify risk of disease incidence in 4 races/ethnicities of the Multi-Ethnic Study of Atherosclerosis (MESA). APPROACH AND
RESULTS: A subcohort of 1323 black, 1677 white, 548 Chinese American, and 1044 Hispanic MESA participants were followed up during a mean 8.5-year period in which 235 incident CHD events were recorded. Lp(a) mass concentrations were measured using a turbidimetric immunoassay. Cox regression analysis determined associations of Lp(a) with CHD risk with adjustments for lipid and nonlipid variables. Lp(a) concentrations were continuously associated with risk of CHD incidence in black (hazard ratio [HR], 1.49; 95% confidence interval [CI], 1.09-2.04] and white participants (HR, 1.22; 95% CI, 1.02-1.45). Examining Lp(a) risk by the 50 mg/dL cut point revealed higher risks of incident CHD in all races except Chinese Americans: blacks (HR, 1.69; 95% CI, 1.03-2.76), whites (HR, 1.82; 95% CI, 1.15-2.88); Hispanics (HR, 2.37; 95% CI, 1.17-4.78). The lower Lp(a) cut point of 30 mg/dL identified higher risk of CHD in black participants alone (HR, 1.87; 95% CI, 1.08-3.21).
CONCLUSIONS: Our findings suggest that the 30 mg/dL cutoff for Lp(a) is not appropriate in white and Hispanic individuals, and the higher 50 mg/dL cutoff should be considered. In contrast, the 30 mg/dL cutoff remains suitable in black individuals. Further research is necessary to develop the most clinically useful Lp(a) cutoff values in individual races/ethnicities.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  continental population groups; coronary disease; lipoprotein(a); risk factor

Mesh:

Substances:

Year:  2015        PMID: 25810300      PMCID: PMC4377643          DOI: 10.1161/ATVBAHA.114.304785

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  24 in total

1.  The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans.

Authors:  V Mooser; D Scheer; S M Marcovina; J Wang; R Guerra; J Cohen; H H Hobbs
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

2.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

3.  Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a).

Authors:  S M Marcovina; J J Albers; A M Scanu; H Kennedy; F Giaculli; K Berg; R Couderc; F Dati; N Rifai; I Sakurabayashi; J R Tate; A Steinmetz
Journal:  Clin Chem       Date:  2000-12       Impact factor: 8.327

4.  Lipoprotein[a] as a risk factor for preclinical atherosclerosis.

Authors:  P J Schreiner; J D Morrisett; A R Sharrett; W Patsch; H A Tyroler; K Wu; G Heiss
Journal:  Arterioscler Thromb       Date:  1993-06

5.  Mechanized lipoprotein(a) assay as a marker for coronary artery disease illustrates the usefulness of high lipoprotein(a) levels.

Authors:  G A Hobbs; I V Kaplan; S S Levinson
Journal:  Clin Chim Acta       Date:  1998-06-08       Impact factor: 3.786

6.  Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  P J Schreiner; G Heiss; H A Tyroler; J D Morrisett; C E Davis; R Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-03       Impact factor: 8.311

7.  Factors associated with coronary artery disease in young population (age ≤ 40): analysis with 217 cases.

Authors:  Wei-xian Yang; Zheng Yang; Yong-jian Wu; Shu-bin Qiao; Yue-jin Yang; Ji-Lin Chen
Journal:  Chin Med Sci J       Date:  2014-03

8.  Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

Authors:  Amit V Khera; Brendan M Everett; Michael P Caulfield; Feras M Hantash; Jay Wohlgemuth; Paul M Ridker; Samia Mora
Journal:  Circulation       Date:  2013-11-17       Impact factor: 29.690

9.  Racial and Ethnic Variation in Lipoprotein (a) Levels among Asian Indian and Chinese Patients.

Authors:  Dipanjan Banerjee; Eric C Wong; Jessica Shin; Stephen P Fortmann; Latha Palaniappan
Journal:  J Lipids       Date:  2011-05-23

10.  Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study.

Authors:  Peter Willeit; Stefan Kiechl; Florian Kronenberg; Joseph L Witztum; Peter Santer; Manuel Mayr; Qingbo Xu; Agnes Mayr; Johann Willeit; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2014-09-02       Impact factor: 24.094

View more
  49 in total

Review 1.  Lipoprotein (a) measurements for clinical application.

Authors:  Santica M Marcovina; John J Albers
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

2.  Evaluating the Potential Association Between Lipoprotein(a) and Atherosclerosis (from the Mediators of Atherosclerosis Among South Asians Living in America Cohort).

Authors:  Mark D Huffman; Namratha R Kandula; Abigail S Baldridge; Michael Y Tsai; Dorairaj Prabhakaran; Alka M Kanaya
Journal:  Am J Cardiol       Date:  2018-12-19       Impact factor: 2.778

3.  Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events.

Authors:  Anand Prasad; Paul Clopton; Colby Ayers; Amit Khera; James A de Lemos; Joseph L Witztum; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-05-04       Impact factor: 8.311

4.  Screening for High Lipoprotein(a).

Authors:  George Thanassoulis
Journal:  Circulation       Date:  2019-03-19       Impact factor: 29.690

Review 5.  Importance of Genetic Studies of Cardiometabolic Disease in Diverse Populations.

Authors:  Lindsay Fernández-Rhodes; Kristin L Young; Adam G Lilly; Laura M Raffield; Heather M Highland; Genevieve L Wojcik; Cary Agler; Shelly-Ann M Love; Samson Okello; Lauren E Petty; Mariaelisa Graff; Jennifer E Below; Kimon Divaris; Kari E North
Journal:  Circ Res       Date:  2020-06-04       Impact factor: 17.367

Review 6.  Biomarkers of Key Biological Pathways in CVD.

Authors:  Nancy Swords Jenny; Nels C Olson; Matthew A Allison; Dena E Rifkin; Lori B Daniels; Ian H de Boer; Christina L Wassel; Russell P Tracy
Journal:  Glob Heart       Date:  2016-09

Review 7.  Interethnic Differences in Serum Lipids and Implications for Cardiometabolic Disease Risk in African Ancestry Populations.

Authors:  Amy R Bentley; Charles N Rotimi
Journal:  Glob Heart       Date:  2017-05-17

8.  Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort.

Authors:  Eric J Brandt; Arya Mani; Erica S Spatz; Nihar R Desai; Khurram Nasir
Journal:  J Clin Lipidol       Date:  2020-07-03       Impact factor: 4.766

Review 9.  Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.

Authors:  Adam N Berman; Ron Blankstein
Journal:  Curr Cardiol Rep       Date:  2019-08-05       Impact factor: 2.931

10.  Lp(a) [Lipoprotein(a)]-Related Risk of Heart Failure Is Evident in Whites but Not in Other Racial/Ethnic Groups.

Authors:  Brian T Steffen; Daniel Duprez; Alain G Bertoni; Weihua Guan; Michael Y Tsai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-10       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.